Pfizer-BioNTech vaccine may require third dose, companies seek approval
The Pfizer-BioNTech Covid-19 vaccine may require a third dose to be more effective against coronavirus (Covid-19), news agencies reported on Friday morning.
The third shot of the Pfizer-BioNTech Covid-19 vaccine is expected to provide better protection against the Beta variant, first identified in South Africa, and the Delta variant which was reported from India. It was found in interim data from an ongoing trial into the vaccine.
Also Read | Gold and Silver prices in India: Gold falls for first time in six days, silver declines too
This will also provide better protection than the current procedure of administering two shots, the companies stated.
The development comes after several reports stated that the vaccine was less effective against the Delta variant of the SARS-CoV-2 virus.
A study, published in the journal 'Nature', stated that a single shot of the Pfizer-BioNTech vaccine, or even the AstraZeneca, "barely" induces any neutralizing antibodies against the Delta variant.
In view of these studies, Pfizer-BioNTech announced that they were working on a Delta-specific vaccine.
-PTC News
